Moderna (MRNA) Total Non-Current Liabilities (2017 - 2026)
Moderna (MRNA) posted quarterly Total Non-Current Liabilities of $3.9 billion for Q2 2026, up 67.71% year-over-year from $2.3 billion in Q2 2025, and up 3.13% on a QoQ basis from $3.8 billion in Q1 2026.
Moderna (MRNA) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Moderna has reported Total Non-Current Liabilities for 10 years, with the latest figure at $3.9 billion in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $3.9 billion, up 67.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.9 billion (up 67.71% YoY), and the FY2025 annual result was $3.4 billion, up 14.43% from the prior year.
- Total Non-Current Liabilities rose to $3.9 billion in Q2 2026, from $3.8 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.4 billion in Q1 2022 and troughed at $2.3 billion in Q2 2025.
- A 5-year average of $4.7 billion and a median of $3.9 billion in 2026 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities plunged 51.17%; it then soared 67.71% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $6.6 billion in 2022, then sank by 34.61% to $4.3 billion in 2023, then tumbled by 31.09% to $3.0 billion in 2024, then climbed by 14.43% to $3.4 billion in 2025, then advanced by 15.07% to $3.9 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $3.9 billion in Q2 2026, $3.8 billion in Q1 2026, and $3.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 3.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92 Bn |
| Mar 31, 2026 | 3.80 Bn |
| Dec 31, 2025 | 3.40 Bn |
| Sep 30, 2025 | 2.52 Bn |
| Jun 30, 2025 | 2.34 Bn |
| Mar 31, 2025 | 2.36 Bn |
| Dec 31, 2024 | 2.97 Bn |
| Sep 30, 2024 | 3.60 Bn |
| Jun 30, 2024 | 3.70 Bn |
| Mar 31, 2024 | 3.65 Bn |
| Dec 31, 2023 | 4.32 Bn |
| Sep 30, 2023 | 5.82 Bn |
| Jun 30, 2023 | 4.76 Bn |
| Mar 31, 2023 | 5.10 Bn |
| Dec 31, 2022 | 6.60 Bn |
| Sep 30, 2022 | 7.98 Bn |
| Jun 30, 2022 | 7.95 Bn |
| Mar 31, 2022 | 10.44 Bn |
| Dec 31, 2021 | 10.45 Bn |
| Sep 30, 2021 | 10.80 Bn |